Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.
May 10, 2020 0 Comments

While the bulk of thyroid cancer sufferers are simply treatable, these with anaplastic or poorly differentiated recurrent thyroid carcinomas have a really poor prognosis with a median survival of lower than a 12 months. Previously, we’ve proven a big correlation between ICAM-1 overexpression and malignancy in thyroid cancer, and have pioneered the use of ICAM-1 …